Dana-Farber News
@DanaFarberNews
Your official source for @DanaFarber Cancer Institute news | Research, science, and innovation | Media requests: [email protected] or 617-632-4090
26-04-2018 19:30:44
2,4K Tweets
5,1K Followers
387 Following
A new study in Journal of Clinical Oncology by Coleman Lindsley & Dana-Farber researchers suggests that allogenic hematopoietic cell transplant should be considered as a viable option for all patients with high-risk MDS, even those with TP53 mutations.
Research Summary ➡️ ms.spr.ly/60119ujKP